Navigation Links
Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Date:5/6/2008

of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits the Company to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Comp
'/>"/>

SOURCE Champions Biotechnology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... (OTCQB: SCLR) announced today that it has launched several ... drug delivery platform, Controlled Delivery Technology ... under various private label brands across the country at ... product has been designed to deliver the full nutritional ...
... Feb. 16, 2012   Remedy Informatics, the leading provider ... Translational research, announced that its Founder and CEO, Gary ... R&D Informatics and Knowledge Management Track on Tuesday, Feb. ... 22 at Molecular Med TRI-CON Feb. 19-23, 2012, in ...
Cached Medicine Technology:SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012 2Remedy Informatics CEO, Gary Kennedy, to Speak at Molecular Med TRI-CON 2Remedy Informatics CEO, Gary Kennedy, to Speak at Molecular Med TRI-CON 3
(Date:7/11/2014)... 11, 2014 Microbiology testing is a ... diagnostics industry, which is expected to pose the biggest ... sector owes its growth to the ongoing spread of ... worldwide and a major factor leading to the upsurge ... bio-terrorism, and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... Utilizing the Keller Funnel, Quatela ... has topped a record number of complication-free breast augmentations. ... 400 successful procedures without the occurrence of a capsular ... across the country for his expertise with the breast ... been the foundation for numerous studies and research. ...
(Date:7/11/2014)... 11, 2014 Ticket Down is a ... Pavilion . When it comes to the summer concert schedule, ... 37-year-old Georgia native is one of the biggest names in country ... Bryan is currently out on his “That’s My Kind of Night” ... the tour will be making through the rest of the summer ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Biostimulants are ... growth in turf and ornamentals. These also help turf ... improve length of roots. Turf, ornamentals, and flowers appear ... Therefore, this usage has increased from the last few ... turf and ornamentals is Europe, with around 40% share ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... HealthDay Reporter , THURSDAY, Aug. 11 (HealthDay News) ... developed after getting tattoos has concluded that both were ... practice. The infections involved Mycobacterium haemophilum ... are compromised. In this instance, however, the patients, both ...
... (AANEM) has awarded accreditation status to four electromyography (EMG) ... in Northeast Ohio. The EMG labs at UH ... Center in Beachwood, Oh., UH University Suburban Health Center ... in Westlake, Oh., received accreditation. UH Case Medical Center ...
... News) -- There,s no strong evidence that taking aspirin ... chances of becoming pregnant, researchers say. Routine use ... that aspirin may improve blood flow to the womb ... may cause pregnancy complications or miscarriage. ...
... THURSDAY, Aug. 11 (HealthDay News) -- The HIV infection rate ... prevalence of AIDS is 10 to 20 times greater than ... indicates. Two percent of poor heterosexuals in those cities ... and Prevention researchers, analysis of National HIV Behavioral Surveillance System ...
... , THURSDAY, Aug. 11 (HealthDay News) -- ... to researchers who used MRI to track the development ... 6 years. At birth, areas of the brain ... such as decision making, self-awareness and creativity are immature ...
... HealthDay Reporter , WEDNESDAY, Aug. 10 (HealthDay News) ... multiple sclerosis (MS) has identified more than 50 gene ... of which are new discoveries. About half of ... system function, and about one-third have been implicated in ...
Cached Medicine News:Health News:New Bacteria Linked to Tattoo Infections 2Health News:New Bacteria Linked to Tattoo Infections 3Health News:Honing in on the Genetics of MS 2Health News:Honing in on the Genetics of MS 3
The SJM Tailor annuloplasty ring, a fully flexible ring, is constructed of a barium-impregnated silicone strip covered with a knitted polyester sewing cuff....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: